Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Current Leases: 2022-2025

Historic Current Leases for Xeris Biopharma Holdings (XERS) over the last 3 years, with Sep 2025 value amounting to $6.2 million.

  • Xeris Biopharma Holdings' Current Leases rose 2.52% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 2.52%. This contributed to the annual value of $6.1 million for FY2024, which is 73.96% up from last year.
  • Xeris Biopharma Holdings' Current Leases amounted to $6.2 million in Q3 2025, which was up 0.62% from $6.2 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Current Leases' 5-year high stood at $6.2 million during Q3 2025, with a 5-year trough of $1.4 million in Q1 2023.
  • Over the past 3 years, Xeris Biopharma Holdings' median Current Leases value was $5.3 million (recorded in 2024), while the average stood at $4.5 million.
  • Data for Xeris Biopharma Holdings' Current Leases shows a peak YoY surged of 219.34% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Xeris Biopharma Holdings' Current Leases stood at $1.6 million in 2022, then surged by 121.20% to $3.5 million in 2023, then surged by 73.96% to $6.1 million in 2024, then rose by 2.52% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q3 2025, $6.2 million for Q2 2025, and $6.1 million during Q1 2025.